SeaSpine Holdings (SPNE) Gets a Buy Rating from Canaccord Genuity
In a report released yesterday, Kyle Rose from Canaccord Genuity maintained a Buy rating on SeaSpine Holdings (SPNE), with a price target of $30.00. The company’s shares closed last Tuesday at $19.99.
According to TipRanks.com, Rose is a 5-star analyst with an average return of 19.6% and a 60.2% success rate. Rose covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Smith & Nephew Snats, and Alphatec Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for SeaSpine Holdings with a $27.00 average price target, representing a 21.9% upside. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $28.00 price target.
See today’s analyst top recommended stocks >>
SeaSpine Holdings’ market cap is currently $598.5M and has a P/E ratio of -13.00. The company has a Price to Book ratio of 3.69.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SeaSpine Holdings Corp. is a medical technology company, which focuses on design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. It has a comprehensive portfolio of orthobiologics and spinal fusion hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. The company was founded on February 12, 2015 and is headquartered in Carlsbad, CA.
Read More on SPNE: